T-cell modulatory properties of CD5 and its role in antitumor immune responses

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Tabbekh, Mouna ^a   Mokrani Hammani, M'Barka ^a   Bismuth, Georges ^b,c,d   Mami Chouaib, Fathia ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT COCHIN   (France)

^c CNRS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Antitumor immune responses; CD5; T cells; Tumor infiltrating T lymphocytes

Indexed keywords

CD5 ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL MATURATION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; HUMAN; IMMUNOBIOLOGY; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE ACTIVATION; THYMOCYTE; TUMOR IMMUNOLOGY;

EID: 84886943815     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22841     Document Type: Article

References (68)

1. Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, et al. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 2004; 5:1143-8; PMID:15475958; http://dx.doi.org/10.1038/ni1129.
2. Terheyden P, Straten P, Bröcker EB, Kämpgen E, Becker JC. CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-gamma-producing T cells from tumor-infiltrating lymphocytes. J Immunol 2000; 164:6633-9; PMID:10843723.
3. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 1997; 186:65-70; PMID:9206998; http://dx.doi.org/10.1084/jem.186.1.65.
4. Boissonnas A, Combadiere C, Lavergne E, Maho M, Blanc C, Debré P, et al. Antigen distribution drives programmed antitumor CD8 cell migration and determines its efficiency. J Immunol 2004; 173:222-9; PMID:15210778.
5. Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med 2007; 204:345-56; PMID:17261634; http://dx.doi. org/10.1084/jem.20061890.
6. Hollenbaugh JA, Reome J, Dobrzanski M, Dutton RW. The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis. J Immunol 2004; 173:1738-43; PMID:15265903.
7. Schüler T, Blankenstein T. Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells. J Immunol 2003; 170:4427-31; PMID:12707316.
8. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Ann rev immunol. 2006; 24:175-208.
9. Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010; 29:1093-102; PMID:19946335; http://dx.doi.org/10.1038/onc.2009.416.
10. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006; 213:131-45; PMID:16972901; http://dx.doi. org/10.1111/j.1600-065X.2006.00442.x.
11. Vazquez-Cintron EJ, Monu NR, Frey AB. Tumorinduced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase. J Immunol 2010; 185:7133-40; PMID:21127315; http://dx.doi. org/10.4049/jimmunol.1001157.
12. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207:2187-94; PMID:20819927; http://dx.doi.org/10.1084/jem.20100643.
13. Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Tötterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 2010; 33:225-35; PMID:20445343; http://dx.doi.org/10.1097/CJI.0b013e3181c01fcb.
14. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011; 71:3540-51; PMID:21430066; http://dx.doi.org/10.1158/0008-5472.CAN-11-0096.
15. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010; 107:4275-80; PMID:20160101; http://dx.doi.org/10.1073/pnas.0915174107.
16. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207:2175-86; PMID:20819923; http://dx.doi.org/10.1084/jem.20100637.
17. Egen JGKM, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3:611-8; PMID:12087419; http://dx.doi.org/10.1038/ni0702-611.
18. Jones NH, Clabby ML, Dialynas DP, Huang HJ, Herzenberg LA, Strominger JL. Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1/Leu-1. Nature 1986; 323:346-9; PMID:3093892; http://dx.doi.org/10.1038/323346a0.
19. Freeman M, Ashkenas J, Rees DJ, Kingsley DM, Copeland NG, Jenkins NA, et al. An ancient, highly conserved family of cysteine-rich protein domains revealed by cloning type I and type II murine macrophage scavenger receptors. Proc Natl Acad Sci U S A 1990; 87:8810-4; PMID:1978939; http://dx.doi. org/10.1073/pnas.87.22.8810.
20. Huang HJ, Jones NH, Strominger JL, Herzenberg LA. Molecular cloning of Ly-1, a membrane glycoprotein of mouse T lymphocytes and a subset of B cells: molecular homology to its human counterpart Leu-1/T1 (CD5). Proc Natl Acad Sci U S A 1987; 84:204-8; PMID:3025855; http://dx.doi.org/10.1073/pnas.84.1.204.
21. Perez-Villar JJ, Whitney GS, Bowen MA, Hewgill DH, Aruffo AA, Kanner SB. CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol Cell Biol 1999; 19:2903-12; PMID:10082557.
22. Berland R, Wortis HH. Origins and functions of B-1 cells with notes on the role of CD5. Ann rev of immunol. 2002; 20:253-300.
23. Osman N, Ley SC, Crumpton MJ. Evidence for an association between the T cell receptor/CD3 antigen complex and the CD5 antigen in human T lymphocytes. Eur J Immunol 1992; 22:2995-3000; PMID:1385158; http://dx.doi.org/10.1002/eji.1830221135.
24. Beyers AD, Spruyt LL, Williams AF. Molecular associations between the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and CD5. Proc Natl Acad Sci U S A 1992; 89:2945-9; PMID:1372996; http://dx.doi.org/10.1073/pnas.89.7.2945.
25. Carmo AM, Castro MA, Arosa FA. CD2 and CD3 associate independently with CD5 and differentially regulate signaling through CD5 in Jurkat T cells. J Immunol 1999; 163:4238-45; PMID:10510361.
26. Biancone L, Bowen MA, Lim A, Aruffo A, Andres G, Stamenkovic I. Identification of a novel inducible cellsurface ligand of CD5 on activated lymphocytes. J Exp Med 1996; 184:811-9; PMID:9064341; http://dx.doi. org/10.1084/jem.184.3.811.
27. Bikah G, Lynd FM, Aruffo AA, Ledbetter JA, Bondada S. A role for CD5 in cognate interactions between T cells and B cells, and identification of a novel ligand for CD5. Int Immunol 1998; 10:1185-96; PMID:9723705; http://dx.doi.org/10.1093/intimm/10.8.1185.
28. Van de Velde H, von Hoegen I, Luo W, Parnes JR, Thielemans K. The B-cell surface protein CD72/Lyb-2 is the ligand for CD5. Nature 1991; 351:662-5; PMID:1711157; http://dx.doi.org/10.1038/351662a0.
29. Calvo J, Padilla O, Places L, Vigorito E, Vilà JM, Vilella R, et al. Relevance of individual CD5 extracellular domains on antibody recognition, glycosylation and co-mitogenic signalling. Tissue Antigens 1999; 54:16-26; PMID:10458319; http://dx.doi. org/10.1034/j.1399-0039.1999.540102.x.
30. Brown MH, Lacey E. A ligand for CD5 is CD5. J Immunol 2010; 185:6068-74; PMID:20952682; http://dx.doi.org/10.4049/jimmunol.0903823.
31. Vera J, Fenutría R, Cañadas O, Figueras M, Mota R, Sarrias MR, et al. The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome. Proc Natl Acad Sci U S A 2009; 106:1506-11; PMID:19141631; http://dx.doi.org/10.1073/pnas.0805846106.
32. Imboden JB, June CH, McCutcheon MA, Ledbetter JA. Stimulation of CD5 enhances signal transduction by the T cell antigen receptor. J Clin Invest 1990; 85:130-4; PMID:1688565; http://dx.doi.org/10.1172/JCI114402.
33. Alberola-Ila J, Places L, Cantrell DA, Vives J, Lozano F. Intracellular events involved in CD5-induced human T cell activation and proliferation. J Immunol 1992; 148:1287-93; PMID:1371522.
34. Tarakhovsky A, Kanner SB, Hombach J, Ledbetter JA, Müller W, Killeen N, et al. A role for CD5 in TCRmediated signal transduction and thymocyte selection. Science 1995; 269:535-7; PMID:7542801; http://dx.doi.org/10.1126/science.7542801.
35. Tarakhovsky A, Müller W, Rajewsky K. Lymphocyte populations and immune responses in CD5-deficient mice. Eur J Immunol 1994; 24:1678-84; PMID:7517879; http://dx.doi.org/10.1002/eji.1830240733.
36. Peña-Rossi C, Zuckerman LA, Strong J, Kwan J, Ferris W, Chan S, et al. Negative regulation of CD4 lineage development and responses by CD5. J Immunol 1999; 163:6494-501; PMID:10586041.
37. Dasu T, Qualls JE, Tuna H, Raman C, Cohen DA, Bondada S. CD5 plays an inhibitory role in the suppressive function of murine CD4(+) CD25(+) T(reg) cells. Immunol Lett 2008; 119:103-13; PMID:18573278; http://dx.doi.org/10.1016/j.imlet.2008.05.008.
38. Ordoñez-Rueda D, Lozano F, Sarukhan A, Raman C, Garcia-Zepeda EA, Soldevila G. Increased numbers of thymic and peripheral CD4+ CD25+Foxp3+ cells in the absence of CD5 signaling. Eur J Immunol 2009; 39:2233-47; PMID:19609976; http://dx.doi. org/10.1002/eji.200839053.
39. Axtell RC, Xu L, Barnum SR, Raman C. CD5-CK2 binding/activation-deficient mice are resistant to experimental autoimmune encephalomyelitis: protection is associated with diminished populations of IL-17-expressing T cells in the central nervous system. J Immunol 2006; 177:8542-9; PMID:17142752.
40. de Wit J, Souwer Y, van Beelen AJ, de Groot R, Muller FJ, Klaasse Bos H, et al. CD5 costimulation induces stable Th17 development by promoting IL-23R expression and sustained STAT3 activation. Blood 2011; 118:6107-14; PMID:21926348; http://dx.doi. org/10.1182/blood-2011-05-352682.
41. Ayyoub M, Raffin C, Valmori D. Generation of Th17 from human naive CD4+ T cells preferentially occurs from FOXP3+ Tregs upon costimulation via CD28 or CD5. Blood 2012; 119:4810-2, author reply 4812-3; PMID:22596172; http://dx.doi.org/10.1182/blood-2012-02-409722.
42. Raman C. CD5, an important regulator of lymphocyte selection and immune tolerance. Immunol Res 2002; 26:255-63; PMID:12403363; http://dx.doi. org/10.1385/IR:26:1-3:255.
43. Gimferrer I, Farnós M, Calvo M, Mittelbrunn M, Enrich C, Sánchez-Madrid F, et al. The accessory molecules CD5 and CD6 associate on the membrane of lymphoid T cells. J Biol Chem 2003; 278:8564-71; PMID:12473675; http://dx.doi.org/10.1074/jbc. M209591200.
44. Brossard C, Semichon M, Trautmann A, Bismuth G. CD5 inhibits signaling at the immunological synapse without impairing its formation. J Immunol 2003; 170:4623-9; PMID:12707340.
45. Bhandoola A, Bosselut R, Yu Q, Cowan ML, Feigenbaum L, Love PE, et al. CD5-mediated inhibition of TCR signaling during intrathymic selection and development does not require the CD5 extracellular domain. Eur J Immunol 2002; 32:1811-7; PMID:12115665; http://dx.doi.org/10.1002/1521-4141(200206)32:6<1811::AIDIMMU1811>3.0.CO;2-G.
46. Azzam HS, DeJarnette JB, Huang K, Emmons R, Park CS, Sommers CL, et al. Fine tuning of TCR signaling by CD5. J Immunol 2001; 166:5464-72; PMID:11313384.
47. Gary-Gouy H, Harriague J, Dalloul A, Donnadieu E, Bismuth G. CD5-negative regulation of B cell receptor signaling pathways originates from tyrosine residue Y429 outside an immunoreceptor tyrosinebased inhibitory motif. J Immunol 2002; 168:232-9; PMID:11751967.
48. Friedlein G, El Hage F, Vergnon I, Richon C, Saulnier P, Lécluse Y, et al. Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death. J Immunol 2007; 178:6821-7; PMID:17513730.
49. Axtell RC, Webb MS, Barnum SR, Raman C. Cutting edge: critical role for CD5 in experimental autoimmune encephalomyelitis: inhibition of engagement reverses disease in mice. J Immunol 2004; 173:2928-32; PMID:15322150.
50. Dennehy KM, Broszeit R, Garnett D, Durrheim GA, Spruyt LL, Beyers AD. Thymocyte activation induces the association of phosphatidylinositol 3-kinase and pp120 with CD5. Eur J Immunol 1997; 27:679-86; PMID:9079809; http://dx.doi.org/10.1002/eji.1830270316.
51. Bamberger MAM, Santos AM, Gonçalves CM, Oliveira MI, James JR, Moreira A, et al. A new pathway of CD5 glycoprotein-mediated T cell inhibition dependent on inhibitory phosphorylation of Fyn kinase. J Biol Chem 2011; 286:30324-36; PMID:21757751; http://dx.doi. org/10.1074/jbc.M111.230102.
52. Azzam HS, Grinberg A, Lui K, Shen H, Shores EW, Love PE. CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity. J Exp Med 1998; 188:2301-11; PMID:9858516; http://dx.doi.org/10.1084/jem.188.12.2301.
53. Fowlkes BJ, Edison L, Mathieson BJ, Chused TM. Early T lymphocytes. Differentiation in vivo of adult intrathymic precursor cells. J Exp Med 1985; 162:802-22; PMID:2863322; http://dx.doi.org/10.1084/jem.162.3.802.
54. Smith K, Seddon B, Purbhoo MA, Zamoyska R, Fisher AG, Merkenschlager M. Sensory adaptation in naive peripheral CD4 T cells. J Exp Med 2001; 194:1253-61; PMID:11696591; http://dx.doi.org/10.1084/jem.194.9.1253.
55. Wong P, Barton GM, Forbush KA, Rudensky AY. Dynamic tuning of T cell reactivity by self-peptidemajor histocompatibility complex ligands. J Exp Med 2001; 193:1179-87; PMID:11369789; http://dx.doi. org/10.1084/jem.193.10.1179.
56. Ernst B, Lee DS, Chang JM, Sprent J, Surh CD. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity 1999; 11:173-81; PMID:10485652; http://dx.doi.org/10.1016/S1074-7613(00)80092-8.
57. Kassiotis G, Zamoyska R, Stockinger B. Involvement of avidity for major histocompatibility complex in homeostasis of naive and memory T cells. J Exp Med 2003; 197:1007-16; PMID:12707300; http://dx.doi. org/10.1084/jem.20021812.
58. Hawiger D, Masilamani RF, Bettelli E, Kuchroo VK, Nussenzweig MC. Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 2004; 20:695-705; PMID:15189735; http://dx.doi.org/10.1016/j.immuni.2004.05.002.
59. Stamou P, de Jersey J, Carmignac D, Mamalaki C, Kioussis D, Stockinger B. Chronic exposure to low levels of antigen in the periphery causes reversible functional impairment correlating with changes in CD5 levels in monoclonal CD8 T cells. J Immunol 2003; 171:1278-84; PMID:12874216.
60. Gagnon J, Chen XL, Forand-Boulerice M, Leblanc C, Raman C, Ramanathan S, et al. Increased antigen responsiveness of naive CD8 T cells exposed to IL-7 and IL-21 is associated with decreased CD5 expression. Immunol Cell Biol 2010; 88:451-60; PMID:20065997; http://dx.doi.org/10.1038/icb.2009.109.
61. Indraccolo SM, Mion M, Zamarchi R, Coppola V, Calderazzo F, Amadori A, et al. A CD3+CD8+ T cell population lacking CD5 antigen expression is expanded in peripheral blood of human immunodeficiency virus-infected patients. Clin Immunol Immunopathol 1995; 77:253-61; PMID:7586735; http://dx.doi. org/10.1006/clin.1995.1151.
62. Dorothée G, Vergnon I, El Hage F, Le Maux Chansac B, Ferrand V, Lécluse Y, et al. In situ sensory adaptation of tumor-infiltrating T lymphocytes to peptide-MHC levels elicits strong antitumor reactivity. J Immunol 2005; 174:6888-97; PMID:15905531.
63. Algarra I, Cabrera T, Garrido F. The HLA crossroad in tumor immunology. Hum Immunol 2000; 61:65-73; PMID:10658979; http://dx.doi.org/10.1016/S0198-8859(99)00156-1.
64. Tabbekh M, Franciszkiewicz K, Haouas H, Lécluse Y, Benihoud K, Raman C, et al. Rescue of tumorinfiltrating lymphocytes from activation-induced cell death enhances the antitumor CTL response in CD5-deficient mice. J Immunol 2011; 187:102-9; PMID:21622855; http://dx.doi.org/10.4049/jimmunol. 1004145.
65. Budd RC. Activation-induced cell death. Curr Opin Immunol 2001; 13:356-62; PMID:11406369; http://dx.doi.org/10.1016/S0952-7915(00)00227-2.
66. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466.
67. Simeone E, Ascierto PA. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J Immunotoxicol 2012; 9:241-7; PMID:22524673; http://dx.doi.org/10.3109/1547691X.2012.678021.
68. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308; PMID:18354418; http://dx.doi.org/10.1038/nrc2355.